-+ 0.00%
-+ 0.00%
-+ 0.00%

INVIVYD PRESENTS VMS063, A POTENTIAL BEST-IN-CLASS MONOCLONAL ANTIBODY CANDIDATE FOR THE TREATMENT AND PREVENTION OF MEASLES, AT IDWEEK 2026

Reuters·10/21/2026 11:04:06